The price-to-earnings ratio for Biogen Inc. (NASDAQ: BIIB) is 13.96x, which is above its average ratio. Moreover, the 36-month beta value for BIIB is 0.14. Analysts have varying opinions on the stock, with 24 analysts rating it as a “buy,” 3 as “overweight,” 9 as “hold,” and 0 as “sell.”
The average price recommended by analysts for Biogen Inc. (BIIB) is $328.18, which is $75.88 above the current market price. The public float for BIIB is 143.87M and currently, short sellers hold a 2.18% of that float. On September 15, 2023, BIIB’s average trading volume was 1.06M shares.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
BIIB) stock’s latest price update
Biogen Inc. (NASDAQ: BIIB)’s stock price has soared by 0.16 in relation to previous closing price of 255.91. Nevertheless, the company has seen a loss of -1.92% in its stock price over the last five trading days. Seeking Alpha reported 2023-09-11 that Biogen Inc. (NASDAQ:BIIB ) Morgan Stanley 21st Annual Global Healthcare Conference September 11, 2023 10:40 AM ET Company Participants Christopher Viehbacher – CEO Conference Call Participants Terence Flynn – Morgan Stanley Terence Flynn Great. Well, thanks for joining us, everybody.
BIIB’s Market Performance
BIIB’s stock has fallen by -1.92% in the past week, with a monthly drop of -5.14% and a quarterly drop of -14.56%. The volatility ratio for the week is 1.42% while the volatility levels for the last 30 days are 1.53% for Biogen Inc. The simple moving average for the past 20 days is -2.65% for BIIB’s stock, with a -9.41% simple moving average for the past 200 days.
Analysts’ Opinion of BIIB
Many brokerage firms have already submitted their reports for BIIB stocks, with HSBC Securities repeating the rating for BIIB by listing it as a “Buy.” The predicted price for BIIB in the upcoming period, according to HSBC Securities is $360 based on the research report published on September 06, 2023 of the current year 2023.
BIIB Trading at -4.94% from the 50-Day Moving Average
After a stumble in the market that brought BIIB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -19.84% of loss for the given period.
Volatility was left at 1.53%, however, over the last 30 days, the volatility rate increased by 1.42%, as shares sank -3.37% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -10.34% lower at present.
During the last 5 trading sessions, BIIB fell by -1.92%, which changed the moving average for the period of 200-days by -15.53% in comparison to the 20-day moving average, which settled at $262.85. In addition, Biogen Inc. saw -7.44% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BIIB starting from Singhal Priya, who sale 431 shares at the price of $269.43 back on Sep 05. After this action, Singhal Priya now owns 3,354 shares of Biogen Inc., valued at $116,124 using the latest closing price.
Singhal Priya, the Head of Development of Biogen Inc., sale 81 shares at $282.87 during a trade that took place back on Jul 03, which means that Singhal Priya is holding 2,924 shares at $22,912 based on the most recent closing price.
Stock Fundamentals for BIIB
Current profitability levels for the company are sitting at:
- +24.11 for the present operating margin
- +70.35 for the gross margin
The net margin for Biogen Inc. stands at +32.30. The total capital return value is set at 11.74, while invested capital returns managed to touch 16.24. Equity return is now at value 19.60, with 10.70 for asset returns.
Based on Biogen Inc. (BIIB), the company’s capital structure generated 50.09 points at debt to equity in total, while total debt to capital is 33.37. Total debt to assets is 27.33, with long-term debt to equity ratio resting at 49.37. Finally, the long-term debt to capital ratio is 32.89.
When we switch over and look at the enterprise to sales, we see a ratio of 4.11, with the company’s debt to enterprise value settled at 0.16. The receivables turnover for the company is 4.60 and the total asset turnover is 0.39. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.99.
Conclusion
To wrap up, the performance of Biogen Inc. (BIIB) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
